Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosine Ingabire

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Human Vaccines & Immunotherapeutics|June 2, 2021
Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in RwandaPaula Mc Kenna, Serge Masyn, Annik Willems, et al.
The Journal of Infectious Diseases|July 1, 2022
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination CampaignJulien Nyombayire, Rosine Ingabire, Ben Magod, et al.
Plos Medicine|February 11, 2025
Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign dataRosine Ingabire, Julien Nyombayire, Amelia Mazzei, et al.
Trials|June 20, 2022
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trialEtienne Karita, Julien Nyombayire, Rosine Ingabire, et al.
Nature Medicine|September 8, 2025
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialJulien Nyombayire, Rosine Ingabire, Amelia Mazzei, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 1, 2016
Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different PopulationsPhilip J Bergin, Robert Langat, Gloria Omosa-Manyonyi, et al.
Science (New York, N.Y.)|May 15, 2025
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansJordan R Willis, Madhu Prabhakaran, Michelle Muthui, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Human Vaccines & Immunotherapeutics|June 2, 2021
Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in RwandaPaula Mc Kenna, Serge Masyn, Annik Willems, et al.
The Journal of Infectious Diseases|July 1, 2022
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination CampaignJulien Nyombayire, Rosine Ingabire, Ben Magod, et al.
Plos Medicine|February 11, 2025
Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign dataRosine Ingabire, Julien Nyombayire, Amelia Mazzei, et al.
Trials|June 20, 2022
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trialEtienne Karita, Julien Nyombayire, Rosine Ingabire, et al.
Nature Medicine|September 8, 2025
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialJulien Nyombayire, Rosine Ingabire, Amelia Mazzei, et al.
Plos One|August 8, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African AdultsJuliet Mpendo, Gaudensia Mutua, Julien Nyombayire, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 1, 2016
Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different PopulationsPhilip J Bergin, Robert Langat, Gloria Omosa-Manyonyi, et al.
Science (New York, N.Y.)|May 15, 2025
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansJordan R Willis, Madhu Prabhakaran, Michelle Muthui, et al.
Pageof 3